Cefoxitin
General
- Type: Second generation cephalosporin
- Dosage Forms: powder for injection
- Dosage Strengths: 1g, 2g, 10g
- Route of Administration: IV
- Common Trade Names: Mefoxin
Adult Dosing
- 1-2g IV q6-8h
Pediatric Dosing
- <3 months old: Safety & efficacy not established
- >3 months old: 80-160 mg/kg/day IV divided q4-6hr; higher dosages should be used for more severe or serious infections
Special Populations
- Pregnancy: Category B
- Lactation: Minimal excretion in breast milk, limited data on affect to infant
- Renal Dosing
- CrCl 30-50 mL/min: 1-2 g q8-12hr
- CrCl 10-30 mL/min: 1-2 g q12-24hr
- CrCl 5-9 mL/min: 500 mg-1 g q24-28hr
- CrCl <5 mL/min: 500 mg-1 g q24-48hr
- Hepatic Dosing: not defined
Contraindications
- Allergy to class/drug
- Neonates
Adverse Reactions
Serious
Common
- Diarrhea
- Anemia, thrombocytopenia, transient leukopenia
- Elevated Cr/BUN
- Elevated LFTs
Pharmacology
- Half-life: 45-60 min
- Metabolism:
- Excretion: Unchanged in urine (85%)
- Mechanism of Action: Inhibits bacterial cell wall synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- Sanford Guide to Antimicrobial Therapy 2014
This article is issued from
Wikem.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.